Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer;ASSOCIATION DE CARBOPLATINE ET ETOPOSIDE DANS LE TRAITEMENT DES RECHUTES DES CANCERS EPITHELIAUX DE L'OVAIRE

Bulletin du Cancer

Volumn 83, Issue 4, 1996, Pages 315-323

  Chauvergne, J ^a   Chinet Charrot, P ^b   Stockle E ^a   Thomas, L ^a   Toulouse, C ^a,c  

^a INSTITUT BERGONIÉ   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c Fed Natl Centres Lutte C ^*  (France)

Author keywords

carboplatin; etoposide; ovarian cancer; salvage chemotherapy

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANISETRON; METHOTREXATE; ONDANSETRON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; MORTALITY; OVARY TUMOR; REVIEW; SALVAGE THERAPY; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ACTUARIAL ANALYSIS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030124138     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Alberts DS, Mason-Liddil N. Carboplatin in the treatment of ovarian cancer. Semin Oncol 1989;16(Suppl 5):19-26
2. Athanassiou AE, Bafaloukos D, Pectasides D, Dimitriadis M, Varthalitis I, Barbounis V. First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. Br J Cancer 1989;60:755-8
3. Van der Burg MEL, Hoff AM, van Lent M, Rodenburg CJ, van Putten WLJ, Stoter G. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 1991;27:248-50
4. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56
5. Calvert AH. Dose optimisation of carboplatin in adults. Anticancer Res 1994;14:2273-8
6. Chambers SK, Chambers JT, Kohorn EI, Schwartz PE. Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer. Gynecol Oncol 1987;27:233-40
7. Chatelut E, Dezeuze A, Lavit M et al. Prédiction de la clairance du carboplatine à partir des caractéristiques morphologiques et biologiques du patient. Bull Cancer 1995;82: 946-53
8. Chauvergne J, Berlie J, Brulé G et al. Data recording in the medical treatment of cancer. In : Mould RF, ed. Computers in radiotherapy and oncology. Bristol: A Hilger, 1984: 129-34
9. Chauvergne J. Nouvelles perspectives des traitements médicaux. In : Querleu D, Cappelaere P, eds. Tumeurs de l'ovaire. Paris: Doin, 1988:177-92
10. Colombo N, Speyer JL, Green M et al. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. Cancer Chemother Pharmacol 1989;23:323-8
11. De Lena M, Lorusso V, Romito S. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma. Cancer Treat Rep 1986;70:893-5
12. Dittrich C, Baur M, Vavra N et al. Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients. Ann Oncol 1993;4:697-9
13. Durand RE, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71:673-9
14. Eckhardt S, Hernadi Z, Thurzo L et al. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid®) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology group (SEEOG) study. Oncology 1990;47:289-95
15. Egorin MJ, Reyno LM, Canetta RM et al. Modeling toxicity and response in carboplatin-based combination chemotherapy. Semin Oncol 1994;21 (Suppl 12):7-19
16. Eiermann W, Achterrath W, Lenaz L, Hepp H. Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study. Cancer Chemother Pharmacol 1991;27:389-93
17. Einhorn LH. Cisplatin plus VP-16 in small-cell lung cancer. Semin Oncol 1986;13:3-4
18. Evans WK, Osoba D, Feld R, Shepherd FA, Bazos MJ, DeBoer G. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 1985;3:65-71
19. Fanning J, Hilgers RD, Hutson E. Carboplatin, etoposide and ifosfamide as second-line treatment for ovarian cancer. Am J Clin Oncol 1994;17:335-7
20. Francis P, Schneider J, Hann L et al. Phase II trial of doce-taxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8
21. Frasci G, Comella G, Comella P et al. Carboplatin (CBDCA) - hexamethylmelamine (HMM) - oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study. Gynecol Oncol 1995;58: 68-73
22. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36:207-11
23. Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol 1995;6:325-41
24. Hainsworth JD, Williams SD, Einhorn LH, Birch R, Greco FA. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern cancer study group trial. J Clin Oncol 1985;3:666-71
25. Hillcoat BL, Campbell JJ, Pepperell R, Quinn MA, Bishop JF, Day A. Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 1985;22:162-6
26. Hoskins PJ, McMurtrie E, Swenerton KD. A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity. Int J Gynecol Cancer 1992; 2:35-40
27. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-3
28. Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10:520-8
29. Kavanagh JJ, Nicaise C. Carboplatin in refractory epithelial ovarian cancer. Semin Oncol 1989;16 (Suppl 5):45-8
30. Kjorstad K, Harris A, Bertelsen K et al. A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report. Ann Oncol 1992;3:217-22
31. Kühnle H, Meerpohl HG, Lenaz L et al. Etoposide in cisplatin-refractory ovarian cancer. Proc Am Soc Clin Oncol 1988;7:137
32. Lorusso V, Catino A, Leone B et al. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 1993;11:1952-6
33. Markman M, Reichman B, Hakes T et al. Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer. Gynecol Oncol 1992;47:353-7
34. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93
35. Marzola M, Zucchetti M, Colombo N et al. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993; 4:517-9
36. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14
37. Muggia FM, Groshen S, Russel C et al. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens. Gynecol Oncol 1993;50:232-8
38. Organisation mondiale de la santé. Notification des résultats du traitement du cancer. Genève: publication offset no 48, 1980
39. Ozols RF. Treatment of ovarian cancer: current status. Semin Oncol 1994;21 (Suppl 2):1-9.
40. Pagani O, Sessa C, Cavalli F. Platinum dose-intensity in solid tumors: pharmacological and clinical perspectives. Bull Cancer 1995;82:16S-23S
41. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39
42. Repetto L, Chiara S, Mammoliti S et al. Crossover study with cisplatin or carboplatin in advanced ovarian cancer. Gynecol Oncol 1990;39:146-9
43. Schabel FM, Trader MW, Laster Jr WR, Corbett TH, Griswold Jr DP. cis-Dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979;63:1459-73
44. Seymour MT, Mansi JL, Gallagher CJ et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-5
45. Sutton GP. Secondary therapy for epithelial ovarian cancer. Semin Oncol 1994;21 (Suppl 7):32-6
46. Thomas L, Pigneux J, Chauvergne J et al. Irradiation abdominopelvienne des cancers ovariens par quatre faisceaux orthogonaux: technique, tolérance, complications. Bull Cancer/Radiother 1993;80:241-8
47. Tonkin KS, Levin L, Powe J. Neither toxicity nor dose intensity of carboplatin is affected by glomerular filtration rate versus body surface area dose calculation in gynecologic malignancy. Int J Gynecol Cancer 1994;4:315-9
48. Uziely B, Groshen S, Jeffers S et al. Paclitaxel (taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol 1994;5:827-33
49. Williams SD, Einhorn LH, Greco FA, Oldham R, Fletcher R. VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer 1980;46:2154-8
50. Williams LL, Fudge M, Burnett LS, Jones HW. Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin. Am J Clin Oncol 1992;15: 331-6
51. De Wit R, van der Burg MEL, van der Gaast A, Logmans A, Stoter G, Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994;5:656-7
52. Wozniak AJ, Biggar S, Samson MK, Corbett TH. In vivo synergy between carboplatin (CBDCA) and etoposide (VP-16) as demonstrated in a murine tumor model. Proc Am Ass Cancer Res 1989;30:541